羅氏開發(fā)新一代DNA測序技術——納米微孔測序技術

瀏覽次數(shù)：5661　發(fā)布日期：2011-10-19　來源：本站　本站原創(chuàng)，轉載請注明出處

羅氏聯(lián)合亞利桑那州立大學、哥倫比亞大學以及IBM研發(fā)新一代DNA測序技術

羅氏于10月11日宣布已與亞利桑那科技公司（Arizona Technology Enterprises，AzTE）簽訂協(xié)議，獲得由亞利桑那州州立大學 Biodesign研究所Dr. Stuart Lindsay以及哥倫比亞大學納米科學研究中心 Dr. Colin Nuckolls 開發(fā)的數(shù)項DNA測序新技術的許可證，這些技術包括DNA堿基探測及讀出方法。至此，羅氏454測序中心將聯(lián)合兩家實驗室以及IBM研發(fā)新一代單分子基于納米微孔技術的DNA測序儀，該技術有望將個人基因組測序成本降到1000美金以下。

這項新技術可以讀出正在通過納米微孔的DNA分子的單個或者幾個堿基，并且已經(jīng)獲得了實驗證實。目前正在研發(fā)第三代DNA堿基解讀分子，以獲得更好的堿基序列讀出。這次簽訂的協(xié)議將推動這些新技術的產(chǎn)業(yè)化。

Dr. Stuart Lindsay是亞利桑那州州立大學 Biodesign研究所單分子生物研究主任，介紹說：“我們的新技術結合了先進的物理、電子、納米科技，將改變DNA測序的基本設計概念，在整個測序過程中不使用化學試劑，將消除測序的試劑成本�！�

羅氏454 Life Sciences公司總裁 Thomas Schinecker先生說：“Biodesign研究所的這個項技術是目前正在發(fā)展的納米微孔測序系統(tǒng)中最好的技術之一，對這個領域的發(fā)展起著非常重要的作用。我們早前已經(jīng)宣布了與IBM公司合作，開發(fā)DNA晶體管技術，而兩者可以很好地結合進一步開發(fā)出新一代超級快速、低成本的DNA測序儀�！�

由IBM公司研發(fā)的DNA晶體管技術，可以控制DNA分子緩慢通過硅晶芯片的納米微孔，而新獲得這項技術可以當DNA分子在通過納米微孔時解碼其堿基序列。兩項技術都基于半導體為基質的納米微孔，比起依賴于蛋白質分子的納米微孔技術更加容易控制、更高產(chǎn)率、更易提高通量及用于工業(yè)生產(chǎn)。

這次的協(xié)議是通過亞利桑那科技公司簽訂的，它是亞利桑那州立大學指定的知識產(chǎn)權管理機構，協(xié)議同時包括了以幫助Lindsay的研究小組將其成果產(chǎn)業(yè)化的一項基金。Lindsay及其同事Bharath Takulapalli最近還獲得了美國國家人類基因組研究中心（NHGRI）頒發(fā)的超過500萬美金的獎金以表彰他們在測序領域的工作。

Roche Licenses Nanopore Sequencing Technologies from Arizona State University and Columbia University for Rapid, Affordable DNA Sequencing

Oct 11, 2011 - fuchsc8

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Arizona Technology Enterprises (AzTE) announced today an agreement to license several technologies developed by Dr. Stuart Lindsay at the Biodesign Institute at Arizona State University and Dr. Colin Nuckolls of the Columbia University Nanoscience Center for the development of a revolutionary DNA sequencing system. The licensed technologies include specialized approaches for DNA base sensing and reading and build on an ongoing collaboration between Roche’s sequencing center of excellence, 454 Life Sciences, and IBM (NYSE: IBM) to develop and commercialize a single-molecule, nanopore DNA sequencer with the capacity to rapidly decode an individual’s complete genome for well below $1000.

The licensed technologies offer novel approaches for reading the sequence of bases, or letters, in a single DNA molecule as it is passed through a nanopore. The team has demonstrated proof-of-concept, and is in the midst of making a third generation reader molecule that provides better discrimination between the DNA bases. The licensing agreement with Roche will help translate these discoveries into a commercial instrument.

“Our promising approach, which combines advances in physics, electronics and nanotechnology, eliminates the need for the use of a major cost of sequencing today – namely, the use of chemical reagents – to read an individual’s genome,” said Lindsay, an ASU Regents’ Professor and Director of the Biodesign Institute’s Center for Single Molecule Biophysics.

“We believe that the DNA reading technologies from the Biodesign Institute are the most advanced available, and will play an important role in our nanopore sequencing system currently under development,” says Thomas Schinecker, President of 454 Life Sciences, a Roche Company, “This will complement the DNA Transistor technology from our previously announced collaboration with IBM very well to form the core of a superior platform for extremely fast, very low-cost genome sequencing.”

The DNA Transistor technology, developed by IBM Research, slows and controls the movement of the DNA molecule as it threads through a microscopic nanopore in a silicon chip, while the newly licensed DNA reading technology can decode the bases of the DNA molecule as it passes through. Both technologies are centered on semiconductor-based nanopores, which have advantages over protein-based nanopores in terms of control, robustness, scalability, and manufacturability.

The deal was brokered by Arizona Technology Enterprises (AzTE), the exclusive intellectual property management and technology transfer organization of Arizona State University, and includes sponsored research funding that will help Lindsay’s team move the technology towards commercialization. The National Human Genome Research Institute (NHGRI), part of the National Institutes of Health (NIH), recently awarded Lindsay and fellow Biodesign researcher Bharath Takulapalli more than $5 million for their work in DNA sequencing. ASU was the only university to receive more than one award.

About Columbia Technology Ventures

A leading academic and research university, Columbia University continually seeks to advance the frontiers of knowledge and to foster a campus community deeply engaged in understanding and addressing the complex global issues of our time. Columbia University's technology transfer office, Columbia Technology Ventures, manages Columbia’s intellectual property portfolio and serves as the university’s gateway for companies and entrepreneurs seeking novel technology solutions. Our core mission is to facilitate the transfer of inventions from academic research to outside organizations for the benefit of society on a local, national and global basis. For more information on Columbia Technology Ventures, please visit www.techventures.columbia.edu

【點擊可查看羅氏診斷產(chǎn)品（上海）有限公司相關產(chǎn)品】

分享到：QQ空間新浪微博騰訊微博微信

【所有新聞】【本類新聞】【相關產(chǎn)品】【關閉窗口】

相關鏈接

本類新聞

關于我們 | 法律聲明 | 廣告報價 | English | 網(wǎng)站地圖